IGF1R and T-cell non-Hodgkin lymphoma: Furthermore, in our lab, we used NPM-ALK+ T-cell lymphoma as a cancer model to identify novel transcriptional and posttranscriptional mechanisms underlying the aberrant increase in IGF-IR expression (Figure 4).